# Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)

> **NCT01311505** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 21 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Myrin© 2 (Rifampicin + Isoniazid)
- **DRUG:** Rimactane® (Rifampicin)

## Key facts

- **NCT ID:** NCT01311505
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2012-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01311505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01311505, "Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01311505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*